Neoadjuvant Icotinib With Chemotherapy for EGFR-mutated Resectable Lung Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
Icotinib is a first-generation inhibitor of EGFR-tyrosine kinase inhibitor in patients with
non-small-cell lung cancer (NSCLC). Here we will evaluate neoadjuvant Icotinib with
chemotherapy prior to surgery, in patients with resectable stage II-IIIB N2 EGFR
mutation-positive NSCLC. The primary endpoint is centrally assessed major pathological
response at the time of resection. Secondary endpoints include pathological complete
response, objective response rate, R0 resection rate at the time of resection, disease-free
survival, and overall survival. Safety and tolerability will also be assessed.